Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SOLV Stock Forecast 2025-2026
$81.90
Current Price
$14.21B
Market Cap
Buy 5
Hold 7
Sell 2
Wall St Analyst Ratings
Distance to SOLV Price Targets
+25.8%
To High Target of $103.00
+3.8%
To Median Target of $85.00
-13.3%
To Low Target of $71.00
SOLV Price Momentum
-3.9%
1 Week Change
+10.9%
1 Month Change
+16.2%
1 Year Change
+24.0%
Year-to-Date Change
-7.1%
From 52W High of $88.20
+34.9%
From 52W Low of $60.70
📊 TOP ANALYST CALLS
Did SOLV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Solventum is one of their latest high-conviction picks.
Latest SOLV Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, SOLV has a neutral consensus with a median price target of $85.00 (ranging from $71.00 to $103.00). The overall analyst rating is Buy (6.7/10). Currently trading at $81.90, the median forecast implies a 3.8% upside. This outlook is supported by 5 Buy, 7 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Patrick Wood at Morgan Stanley, projecting a 25.8% upside. Conversely, the most conservative target is provided by David Roman at Goldman Sachs, suggesting a 13.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SOLV Analyst Ratings
5
Buy
7
Hold
2
Sell
SOLV Price Target Range
Low
$71.00
Average
$85.00
High
$103.00
Current: $81.90
Latest SOLV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SOLV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 2, 2025 | BTIG | Ryan Zimmerman | Buy | Upgrade | $100.00 |
| Nov 10, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $79.00 |
| Nov 7, 2025 | Piper Sandler | Jason Bednar | Overweight | Maintains | $98.00 |
| Oct 1, 2025 | UBS | Kevin Caliendo | Neutral | Initiates | $77.00 |
| Sep 15, 2025 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $82.00 |
| Sep 11, 2025 | Jefferies | Michael Toomey | Hold | Initiates | $80.00 |
| Aug 8, 2025 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $79.00 |
| Aug 8, 2025 | Piper Sandler | Jason Bednar | Overweight | Maintains | $94.00 |
| Jul 15, 2025 | Morgan Stanley | Patrick Wood | Overweight | Upgrade | $103.00 |
| Jul 1, 2025 | Argus Research | John Staszak | Buy | Upgrade | $N/A |
| Jun 6, 2025 | Keybanc | Brett Fishbin | Sector Weight | Initiates | $N/A |
| May 19, 2025 | Piper Sandler | Jason Bednar | Overweight | Upgrade | $87.00 |
| May 9, 2025 | Piper Sandler | Jason Bednar | Neutral | Maintains | $78.00 |
| Apr 30, 2025 | Piper Sandler | Jason Bednar | Neutral | Maintains | $80.00 |
| Mar 5, 2025 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $80.00 |
| Mar 3, 2025 | Mizuho | Steven Valiquette | Neutral | Maintains | $82.00 |
| Mar 3, 2025 | Goldman Sachs | David Roman | Sell | Maintains | $71.00 |
| Feb 28, 2025 | Piper Sandler | Jason Bednar | Neutral | Maintains | $84.00 |
| Feb 28, 2025 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $75.00 |
| Feb 26, 2025 | B of A Securities | Travis Steed | Neutral | Maintains | $85.00 |
Solventum Corporation (SOLV) Competitors
The following stocks are similar to Solventum based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Solventum Corporation (SOLV) Financial Data
Solventum Corporation has a market capitalization of $14.21B with a P/E ratio of 9.2x. The company generates $8.40B in trailing twelve-month revenue with a 18.1% profit margin.
Revenue growth is +0.7% quarter-over-quarter, while maintaining an operating margin of +7.8% and return on equity of +37.3%.
Valuation Metrics
Market Cap
$14.21B
Enterprise Value
$17.82B
P/E Ratio
9.2x
PEG Ratio
0.0x
Price/Sales
1.7x
Growth & Margins
Revenue Growth (YoY)
+0.7%
Gross Margin
+54.2%
Operating Margin
+7.8%
Net Margin
+18.1%
EPS Growth
+937.7%
Financial Health
Cash/Price Ratio
+11.6%
Current Ratio
1.5x
Debt/Equity
103.0x
ROE
+37.3%
ROA
+3.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Solventum Corporation (SOLV) Business Model
About Solventum Corporation
What They Do
Develops healthcare solutions and technologies.
Business Model
Solventum Corporation generates revenue by developing, manufacturing, and commercializing a wide range of healthcare products and services across four main segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company leverages its extensive global presence and workforce to cater to diverse healthcare needs and establish partnerships that enhance its market position.
Additional Information
Founded as an independent company in 2024 after spinning off from 3M, Solventum employs over 20,000 professionals and operates in 38 countries. The company focuses on sustainability and innovation to improve health outcomes, making it a key player in the global healthcare industry.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
22,000
CEO
Mr. Bryan C. Hanson
Country
United States
IPO Year
2024
Website
www.solventum.comSolventum Corporation (SOLV) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing
BDX teams up with ChemoGLO to expand hazardous drug testing, aiming to boost safety in healthcare environments.
Dec 05, 2025
By Zacks Equity Research
Analyst Blog
HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency
Hims & Hers is set to acquire YourBio Health, adding bladeless microneedle tech to transform the blood collection experience.
Dec 04, 2025
By Zacks Equity Research
Analyst Blog
Latest News
These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them?
6 days ago
Quick Summary
Albemarle's lithium products are expanding into new markets, while the recent spinoff Solventum from 3M is establishing its position.
Why It Matters
Albemarle's expansion into new markets for lithium products suggests growth potential, impacting revenue. Solventum's stabilization may enhance 3M's overall value and market perception.
Source: The Motley Fool
Market Sentiment:
Neutral
Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
9 days ago
Quick Summary
Solventum Corporation (SOLV) presented at the Piper Sandler 37th Annual Healthcare Conference, highlighting its developments and strategies in the healthcare sector.
Why It Matters
Solventum Corporation's presentation at a prominent healthcare conference could signal potential growth, partnerships, or innovations, impacting investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Three stocks with over 20% returns in 2025 announced significant buybacks, outperforming the S&P 500's 18% return.
Why It Matters
Buyback announcements from high-performing stocks indicate confidence from management, potentially boosting share prices further and attracting investor interest away from the S&P 500.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Solventum (NYSE: SOLV) will participate in a fireside chat at the Piper Sandler Healthcare Conference on Dec. 2, 2025, at 10:00 a.m.
Why It Matters
Management's participation at a major healthcare conference may signal upcoming developments or strategic insights, potentially impacting Solventum's stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Solventum expands its MedSurg portfolio by entering the $900 million U.S. synthetic tissue matrices market, enhancing its position in the regenerative tissue category.
Why It Matters
The expansion into synthetic tissue matrices positions Solventum to capture a share of the $900 million U.S. market, enhancing growth potential and competitiveness in acute care settings.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Solventum (NYSE: SOLV) announced a $1 billion share repurchase program approved by its Board of Directors, allowing the company to buy back its outstanding common stock.
Why It Matters
Solventum's $1 billion share repurchase program signals confidence in its financial health, potentially boosting share prices and enhancing shareholder value.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SOLV Stock
What is Solventum Corporation's (SOLV) stock forecast for 2026?
Based on our analysis of 14 Wall Street analysts, Solventum Corporation (SOLV) has a median price target of $85.00. The highest price target is $103.00 and the lowest is $71.00.
Is SOLV stock a good investment in 2026?
According to current analyst ratings, SOLV has 5 Buy ratings, 7 Hold ratings, and 2 Sell ratings. The stock is currently trading at $81.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SOLV stock?
Wall Street analysts predict SOLV stock could reach $85.00 in the next 12 months. This represents a 3.8% increase from the current price of $81.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Solventum Corporation's business model?
Solventum Corporation generates revenue by developing, manufacturing, and commercializing a wide range of healthcare products and services across four main segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company leverages its extensive global presence and workforce to cater to diverse healthcare needs and establish partnerships that enhance its market position.
What is the highest forecasted price for SOLV Solventum Corporation?
The highest price target for SOLV is $103.00 from Patrick Wood at Morgan Stanley, which represents a 25.8% increase from the current price of $81.90.
What is the lowest forecasted price for SOLV Solventum Corporation?
The lowest price target for SOLV is $71.00 from David Roman at Goldman Sachs, which represents a -13.3% decrease from the current price of $81.90.
What is the overall SOLV consensus from analysts for Solventum Corporation?
The overall analyst consensus for SOLV is neutral. Out of 14 Wall Street analysts, 5 rate it as Buy, 7 as Hold, and 2 as Sell, with a median price target of $85.00.
How accurate are SOLV stock price projections?
Stock price projections, including those for Solventum Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 4:08 AM UTC